TMEM106B Antikörper (N-Term)
Kurzübersicht für TMEM106B Antikörper (N-Term) (ABIN1450140)
Target
Alle TMEM106B Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- N-Term
-
Kreuzreaktivität (Details)
- Species reactivity (tested):Human.
-
Aufreinigung
- Affinity chromatography purified via peptide column
-
Immunogen
- 15 amino acid synthetic peptide near the amino terminus of Human TMEM106B
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 1.0 mg/mL
-
Buffer
- PBS containing 0.02 % Sodium Azide as preservative
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Avoid repeated freezing and thawing.
-
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- TMEM106B (Transmembrane Protein 106B (TMEM106B))
-
Andere Bezeichnung
- TMEM106B
-
Hintergrund
- Transmembrane protein 106B (TMEM106B) is a single-pass transmembrane protein that is thought to be a novel risk factor for frontotemporal lobar degeneration (FTLD), a group of clinically, pathologically and genetically heterogeneous disorders associated with atrophy in the frontal lobe and temporal lobe of the brain. The actual role of TMEM106B, and that of the closely related protein TMEM106A are still undetermined.Synonyms: Transmembrane protein 106B
-
Gen-ID
- 54664
-
NCBI Accession
- NP_060844
Target
-